These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 37152066)

  • 1. m6A modification on the fate of colorectal cancer: functions and mechanisms of cell proliferation and tumorigenesis.
    Jiang X; Jin Z; Yang Y; Zheng X; Chen S; Wang S; Zhang X; Qu N
    Front Oncol; 2023; 13():1162300. PubMed ID: 37152066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Research progress of N6-methyladenosine in colorectal cancer: A review.
    Lin Y; Shi H; Wu L; Ge L; Ma Z
    Medicine (Baltimore); 2023 Nov; 102(47):e36394. PubMed ID: 38013272
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N6-methyladenine RNA modification and cancer.
    Yang J; Chen J; Fei X; Wang X; Wang K
    Oncol Lett; 2020 Aug; 20(2):1504-1512. PubMed ID: 32724392
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The functions of N6-methyladenosine (m6A) RNA modifications in colorectal cancer.
    Qiao H; Liu L; Chen J; Shang B; Wang L
    Med Oncol; 2022 Sep; 39(12):235. PubMed ID: 36175777
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SRSF9 promotes colorectal cancer progression via stabilizing DSN1 mRNA in an m6A-related manner.
    Wang X; Lu X; Wang P; Chen Q; Xiong L; Tang M; Hong C; Lin X; Shi K; Liang L; Lin J
    J Transl Med; 2022 May; 20(1):198. PubMed ID: 35509101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Physio-pathological effects of N6-methyladenosine and its therapeutic implications in leukemia.
    Liu WW; Wang H; Zhu XY
    Biomark Res; 2022 Aug; 10(1):64. PubMed ID: 35999621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. N6-methyladenosine methyltransferase METTL3 promotes colorectal cancer cell proliferation through enhancing MYC expression.
    Xiang S; Liang X; Yin S; Liu J; Xiang Z
    Am J Transl Res; 2020; 12(5):1789-1806. PubMed ID: 32509177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring m6A methylation in skin Cancer: Insights into molecular mechanisms and treatment.
    Cai M; Li X; Luan X; Zhao P; Sun Q
    Cell Signal; 2024 Dec; 124():111420. PubMed ID: 39304098
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Regulation of N6-Methyladenosine in the Differentiation of Cancer Stem Cells and Their Fate.
    Xu Y; Liu J; Chen WJ; Ye QQ; Chen WT; Li CL; Wu HT
    Front Cell Dev Biol; 2020; 8():561703. PubMed ID: 33072746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recent advances in crosstalk between N6-methyladenosine (m6A) modification and circular RNAs in cancer.
    Huang X; Guo H; Wang L; Yang L; Shao Z; Zhang W
    Mol Ther Nucleic Acids; 2022 Mar; 27():947-955. PubMed ID: 35211355
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The emerging therapeutic target of dynamic and reversible N6-methyladenosine modification during cancer development.
    Liu S; Chen S; Tang C; Zhao Y; Cui W; Jia L; Wang L
    Front Oncol; 2022; 12():970833. PubMed ID: 36226062
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential role of N6-methyladenosine modification in the development of Parkinson's disease.
    Zhou J; Han Y; Hou R
    Front Cell Dev Biol; 2023; 11():1321995. PubMed ID: 38155838
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of circular RNAs and N6-methyladenosine (m6A) modification on cancer biology.
    Zhang G; Hou J; Mei C; Wang X; Wang Y; Wang K
    Biomed Pharmacother; 2023 Mar; 159():114260. PubMed ID: 36657303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. N6-Methyladenosine-Sculpted Regulatory Landscape of Noncoding RNA.
    Zhang Z; Wei W; Wang H; Dong J
    Front Oncol; 2021; 11():743990. PubMed ID: 34722298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-methyladenosine functions and its role in skin cancer.
    Ran Y; Yan Z; Jiang B; Liang P
    Exp Dermatol; 2023 Jan; 32(1):4-12. PubMed ID: 36314059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. N6-methyladenosine-dependent signalling in cancer progression and insights into cancer therapies.
    Tan F; Zhao M; Xiong F; Wang Y; Zhang S; Gong Z; Li X; He Y; Shi L; Wang F; Xiang B; Zhou M; Li X; Li Y; Li G; Zeng Z; Xiong W; Guo C
    J Exp Clin Cancer Res; 2021 Apr; 40(1):146. PubMed ID: 33926508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Main N6-Methyladenosine Readers: YTH Family Proteins in Cancers.
    Dai XY; Shi L; Li Z; Yang HY; Wei JF; Ding Q
    Front Oncol; 2021; 11():635329. PubMed ID: 33928028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. N6-Methyladenosine-Modification-Related Ophthalmic Diseases and Potential Therapeutic Strategies.
    Chen X; Xie Y; Liu Q; Luo X; Gao Y
    Front Biosci (Landmark Ed); 2022 Nov; 27(11):304. PubMed ID: 36472104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR.
    Liu H; Xu Y; Yao B; Sui T; Lai L; Li Z
    Cell Death Dis; 2020 Aug; 11(8):613. PubMed ID: 32792482
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.